Abaxis (ABAX) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend
July 27, 2017 4:01 PM EDTUNION CITY, Calif., July 27, 2017 /PRNewswire/ -- Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the first quarter ended June 30, 2017.
First quarter results include:
Revenues of $58.3 million, up 1% from last year's comparable quarter. Veterinary market revenues of $48.4 million, up 1% over last year's comparable quarter. International revenues of $11.3 million, up 3% over last year's comparable quarter. Revenues from sales of consumables, which include reagent discs, hematology reagent kits,... More